Archimed to take Esperion Therapeutics private in US$1.1B cardiometabolic deal

USA—Healthcare-focused investment firm Archimed has agreed to acquire Esperion Therapeutics in a transaction valued at up to US$1.1 billion, marking a significant shift for the cardiovascular drug developer as it transitions from public to private ownership.

The announcement comes shortly after Esperion invested US$75 million upfront to acquire Corstasis Therapeutics and its congestive heart failure edema treatment, Enbumyst.

Under the terms of the agreement, Archimed will pay US$3.16 per share in cash at closing, representing a 58% premium over Esperion’s closing share price on April 30.

The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.

In addition to the upfront payment, Archimed has structured a contingent value rights (CVR) mechanism that could provide up to US$100 million in additional payments, depending on the future commercial performance of Esperion’s cardiometabolic products.

Contingent Value Rights and performance milestones

The CVR framework ties a portion of the deal’s value to specific sales targets across Esperion’s key therapies.

According to the companies, US$40 million is linked to the performance of cholesterol-lowering drugs Nexletol and Nexlizet in 2027.

To trigger the full payout, combined annual sales must exceed US$350 million.

If sales fall between US$300 million and US$350 million, Archimed will adjust the payout proportionally based on a linear performance formula, ensuring partial value is still delivered to shareholders.

Separately, Enbumyst, a nasal spray therapy for edema associated with congestive heart failure, chronic kidney disease, and liver disease, could unlock an additional $60 million if its annual revenues exceed US$160 million in any single year through 2030.

Portfolio strength and commercial potential

Esperion’s commercial portfolio played a central role in attracting Archimed’s acquisition interest, particularly following its recent expansion through the Corstasis Therapeutics deal.

Enbumyst, which received approval in September, strengthens Esperion’s position in the cardiometabolic and cardiorenal treatment space by offering a loop diuretic administered via nasal spray designed to address fluid overload conditions.

The company has previously indicated that Enbumyst alone represents a potential US$4.6 billion market opportunity in the United States, reflecting growing demand for innovative therapies in heart failure and related chronic conditions.

Meanwhile, Nexletol and Nexlizet continue to serve as key oral therapies targeting LDL cholesterol reduction in patients who require non-statin treatment options.

Strategic rationale and corporate transition

Esperion Therapeutics Chief Executive Officer Sheldon Koenig described the transaction as a pivotal moment for the company, its employees, and its broader healthcare mission.

He noted that the acquisition delivers immediate shareholder value at a premium while also preserving upside participation through the milestone-based CVR structure.

Archimed’s move aligns with a broader strategy of investing in late-stage pharmaceutical assets with established or near-commercial revenue streams, particularly in cardiometabolic care, where long-term demand continues to grow due to the rising global prevalence of cardiovascular disease.

Esperion itself has undergone multiple ownership transitions over the years.

The company was previously associated with Pfizer in the early 2000s before being returned to its founder during a restructuring process.

It later re-emerged as a public company in 2013, building a portfolio focused on cholesterol management and, more recently, broader cardiometabolic therapies.

With the acquisition completed, Esperion will transition to private ownership under Archimed, positioning its drug portfolio for further commercial expansion and potential pipeline development within a more flexible investment structure.